Real-world Outcomes of Multiple Myeloma: Retrospective Analysis
of the Czech Registry of Monoclonal Gammopathies

J 2018

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies

HÁJEK, Roman, Jiří JARKOVSKÝ, Vladimír MAISNAR, Luděk POUR, Ivan ŠPIČKA et. al.

Basic information

Original name

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies

Authors

HÁJEK, Roman (203 Czech Republic, guarantor), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Vladimír MAISNAR (203 Czech Republic), Luděk POUR (203 Czech Republic, belonging to the institution), Ivan ŠPIČKA (203 Czech Republic), Jiří MINAŘÍK (203 Czech Republic), Evžen GREGORA (203 Czech Republic), Petr KESSLER (203 Czech Republic), Michal SÝKORA, Hana FRAŇKOVÁ (203 Czech Republic), Marco CAMPIONI (756 Switzerland), Lucy DECOSTA (826 United Kingdom of Great Britain and Northern Ireland), Maarten TREUR (528 Netherlands), Sebastian GONZALEZ-MCQUIRE (756 Switzerland) and Walter BOUWMEESTER (528 Netherlands)

Edition

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, DALLAS, CIG MEDIA GROUP, LP, 2018, 2152-2650

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.274

RIV identification code

RIV/00216224:14110/18:00104655

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.clml.2018.04.003

UT WoS

000432995800001

Keywords in English

Czech Republic; MM; RMG; Survival; Treatment patterns

Abstract

V originále

The Registry of Monoclonal Gammopathies (RMG) collects long-term data for patients with hematologic malignancies and is one of the largest registries of its type in Europe. The present noninterventional, observational study analyzed real-world data from 2446 Czech patients from the RMG to provide insights into the real-world treatment outcomes of patients with multiple myeloma. Introduction: Real-world data on patient outcomes and treatment patterns in multiple myeloma (MM) are limited. Materials and Methods: The present noninterventional, observational, retrospective analysis of prospectively collected Czech patient medical record data from the Registry of Monoclonal Gammopathies estimated real-world outcomes in adults with a diagnosis of symptomatic MM made between May 2007 and June 2014. Results: In total, 2446 patients had initiated first-line treatment. The median overall survival since the diagnosis (primary endpoint) was 50.3 months (95% confidence interval, 46.1-54.5 months) and decreased with each successive treatment line. A similar trend was observed for progression-free survival and the depth of response. In line with European guidelines and clinical practice, bortezomib-, thalidomide-, and lenalidomide-based regimens were most commonly used across all treatment lines (42.3%, 28.9%, and 18.4%, respectively). In the first line, bortezomib and thalidomide were used most often, with lenalidomide the most commonly used agent in the relapse setting (second to fourth lines). Exploratory analyses revealed that younger age (<= 65 years), lower international staging system stage, and previous stem cell transplantation were associated with significant improvements in overall and progression-free survival, especially in the early treatment lines. Conclusion: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers.

Citovat

HÁJEK, Roman, Jiří JARKOVSKÝ, Vladimír MAISNAR, Luděk POUR, Ivan ŠPIČKA, Jiří MINAŘÍK, Evžen GREGORA, Petr KESSLER, Michal SÝKORA, Hana FRAŇKOVÁ, Marco CAMPIONI, Lucy DECOSTA, Maarten TREUR, Sebastian GONZALEZ-MCQUIRE and Walter BOUWMEESTER. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. DALLAS: CIG MEDIA GROUP, LP, 2018, vol. 18, No 6, p. "E219"-"E240", 22 pp. ISSN 2152-2650. Available from: https://dx.doi.org/10.1016/j.clml.2018.04.003.

@article{1472676,
   author = {Hájek, Roman and Jarkovský, Jiří and Maisnar, Vladimír and Pour, Luděk and Špička, Ivan and Minařík, Jiří and Gregora, Evžen and Kessler, Petr and Sýkora, Michal and Fraňková, Hana and Campioni, Marco and DeCosta, Lucy and Treur, Maarten and GonzalezandMcQuire, Sebastian and Bouwmeester, Walter},
   article_location = {DALLAS},
   article_number = {6},
   doi = {http://dx.doi.org/10.1016/j.clml.2018.04.003},
   keywords = {Czech Republic; MM; RMG; Survival; Treatment patterns},
   language = {eng},
   issn = {2152-2650},
   journal = {CLINICAL LYMPHOMA MYELOMA & LEUKEMIA},
   title = {Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies},
   volume = {18},
   year = {2018}
}

TY  - JOUR
ID  - 1472676
AU  - Hájek, Roman - Jarkovský, Jiří - Maisnar, Vladimír - Pour, Luděk - Špička, Ivan - Minařík, Jiří - Gregora, Evžen - Kessler, Petr - Sýkora, Michal - Fraňková, Hana - Campioni, Marco - DeCosta, Lucy - Treur, Maarten - Gonzalez-McQuire, Sebastian - Bouwmeester, Walter
PY  - 2018
TI  - Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies
JF  - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
VL  - 18
IS  - 6
SP  - "E219"-"E240"
EP  - "E219"-"E240"
PB  - CIG MEDIA GROUP, LP
SN  - 21522650
KW  - Czech Republic
KW  - MM
KW  - RMG
KW  - Survival
KW  - Treatment patterns
N2  - The Registry of Monoclonal Gammopathies (RMG) collects long-term data for patients with hematologic malignancies and is one of the largest registries of its type in Europe. The present noninterventional, observational study analyzed real-world data from 2446 Czech patients from the RMG to provide insights into the real-world treatment outcomes of patients with multiple myeloma. Introduction: Real-world data on patient outcomes and treatment patterns in multiple myeloma (MM) are limited. Materials and Methods: The present noninterventional, observational, retrospective analysis of prospectively collected Czech patient medical record data from the Registry of Monoclonal Gammopathies estimated real-world outcomes in adults with a diagnosis of symptomatic MM made between May 2007 and June 2014. Results: In total, 2446 patients had initiated first-line treatment. The median overall survival since the diagnosis (primary endpoint) was 50.3 months (95% confidence interval, 46.1-54.5 months) and decreased with each successive treatment line. A similar trend was observed for progression-free survival and the depth of response. In line with European guidelines and clinical practice, bortezomib-, thalidomide-, and lenalidomide-based regimens were most commonly used across all treatment lines (42.3%, 28.9%, and 18.4%, respectively). In the first line, bortezomib and thalidomide were used most often, with lenalidomide the most commonly used agent in the relapse setting (second to fourth lines). Exploratory analyses revealed that younger age (<= 65 years), lower international staging system stage, and previous stem cell transplantation were associated with significant improvements in overall and progression-free survival, especially in the early treatment lines. Conclusion: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers.
ER  -

HÁJEK, Roman, Jiří JARKOVSKÝ, Vladimír MAISNAR, Luděk POUR, Ivan ŠPIČKA, Jiří MINAŘÍK, Evžen GREGORA, Petr KESSLER, Michal SÝKORA, Hana FRAŇKOVÁ, Marco CAMPIONI, Lucy DECOSTA, Maarten TREUR, Sebastian GONZALEZ-MCQUIRE and Walter BOUWMEESTER. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. \textit{CLINICAL LYMPHOMA MYELOMA \&{}amp; LEUKEMIA}. DALLAS: CIG MEDIA GROUP, LP, 2018, vol.~18, No~6, p.~''E219''-''E240'', 22 pp. ISSN~2152-2650. Available from: https://dx.doi.org/10.1016/j.clml.2018.04.003.

Detailed Information on Publication Record